Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

OBJECTIVE: To describe detailed MRI results from 2 head-to-head phase III trials, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis Study I (CARE-MS I; NCT00530348) and Study II (CARE-MS II; NCT00548405), of alemtuzumab vs subcutaneous interferon β-1a (SC IFN-β-1a) in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Douglas L., Fisher, Elizabeth, Brinar, Vesna V., Cohen, Jeffrey A., Coles, Alasdair J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W., Stojanovic, Miroslav, Weiner, Howard L., Lake, Stephen L., Margolin, David H., Thomas, David R., Panzara, Michael A., Compston, D. Alastair S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075976/
https://www.ncbi.nlm.nih.gov/pubmed/27590291
http://dx.doi.org/10.1212/WNL.0000000000003169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075976/
https://www.ncbi.nlm.nih.gov/pubmed/27590291
http://dx.doi.org/10.1212/WNL.0000000000003169

Ejemplares similares